Back to Search
Start Over
Health-Related Quality of Life with Gilteritinib Versus Placebo Post-Transplant Maintenance for FLT3-ITD+ Acute Myeloid Leukemia (AML): A Quality of Life Analysis from BMT CTN 1506
- Source :
- Transplantation and Cellular Therapy; February 2024, Vol. 30 Issue: 2, Number 2 Supplement 1 pS44-S45, 2p
- Publication Year :
- 2024
-
Abstract
- The Blood and Marrow Transplant Clinical Trials Network study 1506 (NCT02997202) was a multi-center phase III randomized trial comparing gilteritinib versus placebo after allogeneic hematopoietic cell transplantation (HCT) in patients with FLT3-ITD-positive AML. The primary analysis comparing relapse-free survival (RFS) did not reach statistical significance, with higher treatment-emergent adverse events (TEAE) with gilteritinib. In patients with detectable FLT3-ITDmeasurable residual disease (MRD) peri-HCT, gilteritinib was associated with significantly longer RFS, demonstrating efficacy of MRD monitoring and intervention with FLT3 inhibition in MRD positive patients. The impact of gilteritinib maintenance on health-related quality of life (HRQoL) is not known; and the aim of this prespecified exploratory analysis is to describe the effect of gilteritinib versus placebo on HRQoL.
Details
- Language :
- English
- ISSN :
- 26666375 and 26666367
- Volume :
- 30
- Issue :
- 2, Number 2 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Transplantation and Cellular Therapy
- Publication Type :
- Periodical
- Accession number :
- ejs65462632
- Full Text :
- https://doi.org/10.1016/j.jtct.2023.12.077